This site is intended for health professionals only
Monday 27 May 2019
Share |

FDA approves chemotherapy drug

The FDA has given Sagent Pharmaceuticals the go-ahead to market Mesna, a drug used to cut the risk of haemorrhagic cystitis arising from ifosfamide chemotherapy.

The treatment, a generic version of Baxter's Mesnex, is administered by means of an injection. It will be sold in 1 mg per 10 ml multi-dose vials, offered in single doses and packs of 10.

Spokesman Jeffrey Yordon said: "Mesna is our second addition this month to our cancer supportive care product line, allowing Sagent's sales teams to provide customers with an expanding range of products for oncology patients."

Mesna is the latest product to be approved as part of the company's joint venture with Strides Arcolab.

The deal sees Sagent take primary responsibility for marketing the drug in the United States.

Copyright Press Association 2010
Sagent Pharmaceuticals

Ads by Google

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?


Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.



Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher